Floatz logo

Ramosetron

Solid Tumour

Hallym University Medical CenterSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

18 Active assets in the Solid Tumour cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Henlix, Inc
Phase 2B
Atezolizumab
Genentech, Inc.
Phase 2/3B
Entrectinib
Cancer Research UK
Phase 2/3B
ALECTINIB
Cancer Research UK
Phase 2/3B
Dabrafenib
Cancer Research UK
Phase 2/3B

View all 36 →

Same molecule, other indications

Ramosetron is also rated in:

breast cancerDormant
BB
Indicative ·
68 / 100
View asset →
Uterine Myoma, Ovary Neoplasm, AdenomyosisDormant
B
Indicative ·
60 / 100
View asset →
chemotherapy-induced toxicityDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →